THE WELCH COMPANY
440 Davis Court #1602
San Francisco, CA 94111-2496
415 781 5700
rodwelch@pacbell.net


S U M M A R Y


DIARY: February 4, 2009 05:47 PM Wednesday; Rod Welch

Millie receives Stritter research on treating cancer as chronic disease
after UCSF achieves local control of expanding IBC.

1...Summary/Objective
2...Treatment Options Following Hyperthermia for Chronic Cancer Care
....Treatment Options Patient Profile


..............
Click here to comment!

CONTACTS 

SUBJECTS
2nd Opinion Retainer $300 Scope of Work  Rceived Support Medical Tea

1803 -
1803 -    ..
1804 - Summary/Objective
1805 -
180501 - Follow up ref SDS 81 0000. ref SDS 78 0000.
180502 -
180503 -
180504 -
180506 -  ..
1806 -
1807 -
1808 - Background
1809 -
180901 - Prior work with Doctor Stritter is reported on 090106. ref SDS 49 KI5I
180902 - This record focuses on 2nd opinion for strategy to treat cancer as a
180903 - chronic disease after recovering from 6th relapse of IBC by achieving
180904 - local control with hyperthermia treatments at UCSF...
180905 -
180906 -    1.  Millie met Doctor Stritter during
180907 -        seminar presentation at Wellness
180908 -        Community cancer support
180909 -        group.............................. 081018, ref SDS 29 PQ6X
180911 -         ..
180912 -    2.  Doctor Stritter asked for copies of
180913 -        correspondence with the medical team
180914 -        on Millie's response to sunitinib
180915 -        treatment for cancer that supports
180916 -        Doctor Stritter's research on
180917 -        advanced cancer
180918 -        treatments......................... 081018, ref SDS 29 1Y4G
180920 -         ..
180921 -    3.  Doctor Stritter was helpful finding
180922 -        referral for resolving payment issues
180923 -        with Kaiser for Millie's treatment
180924 -        on referral to UCSF................ 081114, ref SDS 33 638G
180926 -         ..
180927 -    4.  Millie was confused, worried, and
180928 -        emotional about plans to maintain
180929 -        strong recovery from cancer and reduce
180930 -        side effects by adjusting treatments
180931 -        to tolerable levels on 081226,
180932 -        presented during meeting at
180933 -        UCSF............................... 081218, ref SDS 41 QW48
180934 -        as set out in the letter confirming
180935 -        understandings to the medical
180936 -        team............................... 081218, ref SDS 42 GF4V
180937 -        Millie submitted a copy to Doctor
180938 -        Stritter of the letter on 081218 to
180939 -        the medical team reporting results of
180940 -        examination at
180941 -        UCSF............................... 081218. ref SDS 42 4P7F
180943 -         ..
180944 -    5.  Millie sent a copy to Doctor Stritter
180945 -        of another letter to the primary care
180946 -        physician at Kaiser on 081219, requesting
180947 -        assistance managing the work plan at
180948 -        UCSF for Millie's treatment with
180949 -        sunitinib.......................... 081219, ref SDS 44 KY8Q
180950 -        noting that case management is
180951 -        difficult due to limited time and emotional
180952 -        feelings that prevent thorough analysis
180953 -        during meetings with
180954 -        doctors............................ 081219, ref SDS 44 SU8X
180956 -         ..
180957 -    6.  Millie's letter to Doctor Stritter
180958 -        requested second opinion on Millie's
180959 -        treatment with sunitinib staying at
180960 -        full strength and reducing or ending
180961 -        treatment with cyclophosphamide
180962 -        to reduce side
180963 -        effects............................ 081220, ref SDS 45 I69Q
180965 -         ..
180966 -    7.  Millie received a letter from Doctor
180967 -        Stritter with terms and conditions for
180968 -        2nd opinion, and transmitting a pdf file
180969 -        requesting patient history in a
180970 -        questionnaire...................... 081223, ref SDS 46 8N9M
180972 -         ..
180973 -    8.  Questionnaire could not be filled out
180974 -        in pdf file because Adobe Acrobat
180975 -        could not be configured; information
180976 -        requested in the form was
180977 -        entered in the
180978 -        record............................. 081223, ref SDS 46 DQ6J
180980 -         ..
180981 -    9.  Patient history for Doctor Stritter's
180982 -        2nd opinion support was developed
180983 -        in the SDS record.................. 090106, ref SDS 49 IP6H
180985 -         ..
180986 -   10.  Millie sent letter to Doctor Stritter
180987 -        with payment of $300 for 2nd
180988 -        opinion services................... 090106, ref SDS 49 S34O
180989 -        and listing objectives for
180990 -        conslutation....................... 090106, ref SDS 49 6H3Q
180992 -         ..
180993 -   11.  Doctor Stritter notified Millie that
180994 -        she was attending a professional conference
180995 -        on integrative oncology conference in
180996 -        Florida, and would respond to
180997 -        Millie's letter on
180998 -        090114............................. 090107, ref SDS 51 PJ3I ,
181000 -         ..
181001 -   12.  Doctor Stritter called and advised she
181002 -        needs another $300 to provide a 2nd
181003 -        opinion on treatments for
181004 -        Millie............................. 090114, ref SDS 52 U290
181005 -        doctor requested support reviewing
181006 -        Millie's complex patient history
181007 -        for 2nd opinion
181008 -        work............................... 090114, ref SDS 52 U271
181010 -         ..
181011 -   13.  Millie sent a letter to Doctor Stritter,
181012 -        ref SDS 55 3C5O, following up the letter
181013 -        on 090106 setting out scope of assignment,
181014 -        ref SDS 49 S34O, confirming understandings
181015 -        from the call on 090114, and submitting
181016 -        additional information on pathology
181017 -        reports and CT tests requested
181018 -        by the doctor...................... 090119, ref SDS 52 U271
181020 -         ..
181021 -   14.  Called Doctor Stritter who asked for
181022 -        information in a questionaire she
181023 -        submitted with a letter to Millie on
181024 -        091223, ref SDS 46 DQ6J, the doctor
181025 -        wants another $300 to provide a list
181026 -        of treatments that can
181027 -        help Millie........................ 090120, ref SDS 56 CM66
181029 -         ..
181030 -   15.  Millie sent a letter to Stritter Medical
181031 -        Consulting transmitting information
181032 -        requested in the Questionnaire
181033 -        received in the record on
181034 -        081223............................. 090121, ref SDS 57 C57O
181036 -         ..
181037 -   16.  Regrettably, time has become a factor
181038 -        because the cancer marker jumped to
181039 -        CA 15-3 303 for the lab on 090116.
181040 -        ref SDS 53 PQTQ; Millie needs
181041 -        input as soon as
181042 -        possible........................... 090121, ref SDS 57 SC5T
181044 -         ..
181045 -   17.  Dislocated shoulder from fall treatment
181046 -        in Emergency Department on 090122, and
181047 -        notice that UCSF ended Millie's
181048 -        treatment with sunitinib due to 6th
181049 -        relapse of IBC, and rising side
181050 -        effects; copy of letter to
181051 -        medical team sent to Doctor
181052 -        Stritter........................... 090123, ref SDS 60 KR4P
181054 -         ..
181055 -   18.  Millie letter notified Doctor Stritter
181056 -        that UCSF ended treatment with sunitinib
181057 -        due progression of
181058 -        disease............................ 090126, ref SDS 63 Q59G
181059 -        Millie meeting with UCSF on 090129
181060 -        asks Doctor Stritter for
181061 -        treatment options.................. 090126, ref SDS 63 066T
181063 -         ..
181064 -   19.  Doctor Stritter letter proposes teleon
181065 -        2nd opinion on 090203 or on 090205 at
181066 -        1600, and needs payment of another
181067 -        $300 paymnet in advance of
181068 -        consultation....................... 090127, ref SDS 64 L24J
181070 -         ..
181071 -   20.  Millie submitted payment of $300 and
181072 -        requests consultation on 090203,
181073 -        requests receipt................... 090127, ref SDS 64 HO5W
181075 -         ..
181076 -   21.  Doctor Stritter receives payment;
181077 -        says cannot have telecon on 090203;
181078 -        asks about having consultation
181079 -        on 090205 1600..................... 090130, ref SDS 67 4W6L
181081 -         ..
181082 -   22.  Millie responds to Gwen's letter on
181083 -        090130, ref SDS 67 4W6L, reports cancer
181084 -        is progressing [see Millie's letter to
181085 -        medical team on 090130, ref SDS 68 AY7X,
181086 -        and lining up treatment
181087 -        options has been
181088 -        difficult.......................... 090131, ref SDS 69 4W6L
181089 -        and shown in the letter to the
181090 -        medical team on 090130, with a copy
181091 -        to Gwen. ref SDS 68 W858
181093 -         ..
181094 -   23.  Primary objective for Stritter Medical
181095 -        is to submit research and written opinion
181096 -        listing treatments for IBC, and sources
181097 -        for Millie's complex patient profile,
181098 -        shown in Millie's letter to
181099 -        Gwen............................... 090131, ref SDS 69 H95S
181100 -        Obvious question is are there
181101 -        other treatments that can
181102 -        help me............................ 090131, ref SDS 69 H96U
181104 -         ..
181105 -   24.  Agenda requested a day or so before
181106 -        telecon consultation with a partial
181107 -        list of possible treatments, so
181108 -        people can be prepared with
181109 -        focused questions.................. 090131, ref SDS 69 H96X
181111 -         ..
181112 -   25.  Millie receives letter from Gwen
181113 -        reporting plans to submit preliminary
181114 -        research on 090203 in time to be
181115 -        prepared for telephone conference
181116 -        on 090205 1600; recommends start
181117 -        Doxil and hyperthermia
181118 -        at UCSF............................ 090202, ref SDS 72 EF9M
181120 -         ..
181121 -   26.  Millie received letter from Gwen
181122 -        transmitting preliminary research
181123 -        for cancer treatments that fit Millie's
181124 -        complex patient profile that requires
181125 -        continuing treatment for cancer as a
181126 -        chronic disease after hyperthermia and
181127 -        lower dose radiation at UCSF to achieve
181128 -        local control, and implements planning
181129 -        presented in Gwen's letter on 090202,
181130 -        ref SDS 73 EF9M, which responded to
181131 -        Millie's request in a letter to
181132 -        Stritter Medical Consulting on
181133 -        090131, ref SDS 70 H96X, for
181134 -        an agenda to guide telecon
181135 -        consultation scheduled
181136 -        for 090205......................... 090203, ref SDS 78 CF7J
181138 -         ..
181139 -   27.  On 090204 0257 Millie notifies Gwen that preliminary report
181140 -        from Stritter Medical Consulting, received on 090203 2257,
181141 -        ref SDS 78 CF7J, aligns with requirements for listing possibile
181142 -        treatments for Millie after hyperthermia treatment at UCSF
181143 -        achieves local control of expanding IBC; provides agenda to
181144 -        discuss in telecon conference on 090205 1600 strategy to
181145 -        transition, when needed in a few weeks, or hopefully many
181146 -        months toward treating cancer as a chronic disease. ref SDS 81
181147 -        7P9O
181149 -         ..
181150 -   28.  On 090204 0257 Millie's letter to Stritter Medical Consulting
181151 -        asks for comment on research indicating treatment strategy
181152 -        evaluating blood or tissue, ref SDS 81 FQ3W, in this case IBC
181153 -        infected skin, for testing in a laboratory to discover the most
181154 -        effective cancer treatment, shown in the record on 090129.
181155 -        ref SDS 66 YL7G
181156 -
181157 -
181158 -
1812 -

SUBJECTS
Cancer Treatments Chronic Disease Strategy Clinical Studies Trials a

3103 -
3104 - Progress
310501 -  ..
310502 - Treatment Options Following Hyperthermia for Chronic Cancer Care
310503 -
310504 - Millie receives Gwen's letter responding to Millie's letter sent
310505 - earlier this morning on 090204 0257, ref SDS 81 7P9O
310507 -  ..
310508 - This is the 7th second opinion Millie has consulted to support the
310509 - medical team caring for Millie's cancer, listed in case study on
310510 - 080110. ref SDS 24 F47O
310512 -  ..
310513 - Gwen transmits report on treatments after hyperthermia at UCSF
310514 - achieves local control of Millie's IBC, and when Millie will require a
310515 - strategy for continuing treatment of cancer as a chronic disease,
310516 - shown in Millie's letter to UCSF earlier this morning on 090204 0219
310517 - calling for teamwork between Kaiser and UCSF, and between UCSF Breast
310518 - Care Clinic, and Radiation Oncology, supervised by Doctor Rugo,
310519 - ref SDS 80 278Q, and further requesting medical opinion on teatments
310520 - after hyperthermia. ref SDS 80 278T
310521 -
310522 -    1.  Subject:  Oncology Strategy Case Management
310523 -        Date: Wed, 4 Feb 2009 16:36:31 -0800
310530 -         ..
310531 -    3.  Here is the final report.  Please make sure you delete the
310532 -        preliminary report so there are no mix-ups.
310533 -
310534 -            [On 090218 0828 received follow up letter from Gwen
310535 -            submitting article on Thermodox used with hyperthermia.
310536 -            ref SDS 85 7Q7J
310538 -         ..
310539 -    4.  I look forward to our talk tomorrow!
310540 -
310541 -            [On 090205 telecon consultation with Gwen. ref SDS 82 I36H
310542 -
310543 -            [On 090206 Gwen notes that Millie's case is inspirational
310544 -            surviving a very aggressive cancer and complex case
310545 -            management for so many years. ref SDS 83 7Q7J
310546 -
310552 -  ..
310553 - Attached to Gwen's letter is a report...
310554 -
310555 -            [On 090205 telecon conference discussed Gwen's report.
310556 -            ref SDS 82 NM4H
310558 -     ..
310559 -    Treatment Options Patient Profile
310560 -
310561 -    This is the content of Gwen's report, ref DRT 1 0001, with some
310562 -    edits for clarification...
310563 -
310564 -    Gwen seems to present 5 approaches...
310565 -
310566 -        A.  MD Anderson 2nd opinion IBC research lab. ref SDS 0 4R3S
310567 -        B.  Chemotherapy clinical trials. ref SDS 0 UK62
310568 -
310569 -            [On 090218 0828 received follow up letter from Gwen
310570 -            submitting article on Thermodox used with hyperthermia.
310571 -            ref SDS 85 7Q7J
310573 -             ..
310574 -        C.  Vaccine clincial trials. ref SDS 0 4S3P
310575 -        D.  Test Tissue for most effective treatment. ref SDS 0 9K9W
310576 -        E.  Document/Literature/Conference review. ref SDS 0 9K5R
310577 -
310578 -    1.  Diagnosis:
310579 -
310580 -        a.  6th Relapse secondary inflammatory breast cancer (IBC)
310581 -            January 22, 2009  Requires urgent treatment quickly to
310582 -            prevent losing local control.
310584 -             ..
310585 -        b.  ER-negative, PR-negative, HER2-negative
310587 -             ..
310588 -        c.  Pulmonary embolism treatment wafarin (Coumadin) daily.
310590 -             ..
310591 -        d.  Dislocated right shoulder January 22, 2009
310593 -         ..
310594 -    2.  Purpose 2nd Opinion
310595 -
310596 -        Quality of life strategy identify treatments for cancer as
310597 -        chronic disease, after hyperthermia achieves local control in
310598 -        about 6 weeks.  Treatments sustain qualify of life through
310599 -        synergy with natural immunity.from patients lifestyle of
310600 -        vigorous exercise. ref DRT 1 VK7P
310602 -  ..
310603 - Aligns with the record on 090106 submitted to Stritter Consulting on
310604 - purpose of 2nd opinion. ref SDS 49 PQ6Q
310606 -  ..
310607 - Millie's objective was presented to UCSF in a letter this morning on
310608 - 090204 0217. ref SDS 80 278T
310610 -  ..
310611 - Stritter opinion continues...
310612 -
310613 -    3.  Status:
310614 -
310615 -        Begin hyperthermia with lower dose radiation scheduled February
310616 -        19, 2009 at UCSF to achieve local control by reversing
310617 -        currently expanding IBC.
310619 -         ..
310620 -    4.  Treatments to date:, ref DRT 1 J48K
310621 -
310622 -            1.  Left breast lumpectomy sentinal node disection 2002
310623 -            2.  Adriamycin/Cytoxan 2002
310624 -            3.  Radiation 2002
310625 -            4.  Taxotere 2002
310626 -            5.  Taxol/Avastin 2004
310627 -            6.  Adriamycin/Cytoxan 2005
310628 -            7.  Taxotere/Xeloda 2005
310629 -            8.  Mastectomy 2005
310630 -            9.  Taxotere/Xeloda 2006
310631 -           10.  Carboplatin/Erbitux (cetuximab) 2007 and 2008
310632 -           11.  Sutent/Methotrexate/Cytoxan 2008
310633 -           12.  Hyperthermia with lower dose radiation 2009
310635 -  ..
310636 - Aligns patient history submitted to Stritter consulting on 090106.
310637 - ref SDS 49 K87F
310639 -                 ..
310640 -                [On 090213 1140 Millie's treatment history listed
310641 -                during meeting with Doctor Johnson, Millie's primary
310642 -                care physician at Kaiser. ref SDS 84 ES7I
310643 -
310645 -  ..
310646 - Stritter opinion continues...
310647 -
310648 -    5.  Treatment Options (generally in the order of importance)
310649 -
310650 -        {supplements prior listing of treatment options proposed by
310651 -        UCSF listed in the record on 090121 1017. ref SDS 58 EV53}
310653 -                ..
310654 -               [On 090206 Gwen notes that Millie's case is inspirational
310655 -               surviving a very aggressive cancer and complex case
310656 -               management for so many years. ref SDS 83 7Q7J
310657 -
310658 -        a.  MD Anderson IBC Research Center
310660 -             ..
310661 -            Evaluation and Treatment (on-site or in conjunction with
310662 -            Kaiser oncologists) at the top inflammatory breast cancer
310663 -            center in the country: MD Anderson Cancer Center,
310664 -            Houston, TX
310666 -             ..
310667 -            Doctor Massimo Cristofanilli is the co-director of their
310668 -            IBC clinic; 1-877-MDA-6789
310670 -             ..
310671 -            In December 2008, held the first ever IBC conference; if
310672 -            you are interested, I could obtain the research presented
310673 -            at this conference
310675 -             ..
310676 -            They could also give you a second opinion on the lymph node
310677 -            biopsy done 11/7/08 (no appointment required usually)
310679 -             ..
310680 -            In 5% - 10% of cases, initial biopsy analysis will be
310681 -            incorrect.  Review therefore yields additional treatment
310682 -            options in some cases.  The patient requests the biopsy
310683 -            slide from the laboratory at Kaiser, similiar to getting a
310684 -            second opinion, and mail to the MD Anderson
310686 -             ..
310687 -        b.  Participation in clinical trials (but must meet their
310688 -            eligibility requirements)
310689 -
310690 -            1.  Phase I/II study of GM-CSF vaccine therapy with
310691 -                interferon alfa and Cytoxan; Good Samaritan
310692 -                Hospital, Los Angeles, Ca; Charles Wiseman, MD;
310693 -                primary investigator; contact: Cary H. Gota, MD at
310694 -                213-977-1214; Dr. Wiseman has been doing cancer
310695 -                immunotherapy for many, many years
310696 -
310697 -                   [On 090218 0828 received follow up letter from Gwen
310698 -                   submitting article on Thermodox used with
310699 -                   hyperthermia. ref SDS 85 7Q7J
310701 -                    ..
310702 -                   [On 090220 1548 paper received from UCSF on
310703 -                   hyperthermia explains options combining with
310704 -                   chemotherapy, ref SDS 86 0129, and biological
310705 -                   vaccines. ref SDS 86 0164
310707 -                    ..
310708 -                   [On 090312 0830 meeting with Tara says Doctor Rugo
310709 -                   planning treatments for Millie after radiation and
310710 -                   hyperthermia. ref SDS 87 SS4F
310712 -                    ..
310713 -                   [On 090312 0830 Doctor Hsu advises UCSF Radiology
310714 -                   Oncology Department has more treatments that can
310715 -                   help Millie recover from IBC. ref SDS 87 F973
310717 -                    ..
310718 -                   [On 090326 0054 research on treating Millie's cancer
310719 -                   as chronic disease submitted to medical team, at
310720 -                   request of primary care physician. ref SDS 89 DW5S
310722 -                 ..
310723 -            2.  Phase I/II study of Rexin-G, a viral vector oncocidal
310724 -                gene therapy for breast cancer; Epeius Clinical
310725 -                Research Unit; San Marino, Ca; Sant Chawla,
310726 -                primary investigator; 310-552-9999; the theory
310727 -                behind this vaccine is impeccable
310729 -                 ..
310730 -            3.  Phase II study of Casodex (Bicalutamide) in
310731 -                androgen receptor-positive, triple-negative BC;
310732 -                Memorial Sloan-Kettering Cancer Center, NY;
310733 -                Clifford Hudis, primary investigator; 212-639-5449; but
310734 -                tumor must be tested for androgen-receptor first
310736 -                 ..
310737 -            4.  Phase II study of AZD0530, a Src inhibitor for triple-
310738 -                negative BC; Memorial Sloan-Kettering Cancer
310739 -                Center, NY; Dr. Tiffany A. Traina, primary investigator;
310740 -                212-639-5209
310742 -                 ..
310743 -            5.  Phase IIb study of Gemzar +/-Nexavar:  Memorial
310744 -                Sloan-Kettering Cancer Center, NY; Clifford Hudis,
310745 -                primary investigator; 212-639-5449; Nexavar as anti-
310746 -                VEGF activity like Avastin but without the blood clot
310747 -                risk; of note, Nexavar is similar to but not the same
310748 -                as Sutent (sunitinib used for Millie's 5th relapse
310749 -                beginning on November 13, 2008, and ended on January
310750 -                22, 2009)
310752 -                 ..
310753 -            6.  Phase 1 study of PARP inhibitor; this drug is showing
310754 -                exciting activity against BRCA-positive tumors (most
310755 -                BRCA+ tumors are triple negative); multiple studies in
310756 -                multiple locations:
310757 -
310758 -                •  National Cancer Insitute, Bethesda, MD;
310759 -                   clinicaltrials.gov identifier NCT00749502,
310760 -                   NCT00553189, NCT00647062
310762 -                    ..
310763 -                •  Tampa, FL sponsored by Merck;
310764 -                   clinicaltrials.gov identifier NCT00749502;
310765 -                   contact 888-577-8839
310766 -
310767 -                      [On 090326 0054 research on treating Millie's
310768 -                      cancer as chronic disease submitted to medical
310769 -                      team, at request of primary care physician.
310770 -                      ref SDS 89 DW5S
310772 -                       ..
310773 -                      [On 090326 1733 Doctor Johnson responded in a
310774 -                      letter saying he plans to talk about this at the
310775 -                      next meeting. ref SDS 90 WR5O
310777 -                       ..
310778 -                      [On 090616 1245 Doctor Rugo reports UCSF and
310779 -                      Kaiser have agreed that Millie's next treatment
310780 -                      at UCSF after MPA will be with PARP. ref SDS 91
310781 -                      KD6L
310783 -                       ..
310784 -                      [On 090617 0112 Millie notifies medical team
310785 -                      Doctor Rugo reports everybody at Kaiser and UCSF
310786 -                      is "on board" to treat Millie's cancer as a
310787 -                      chronic disease, ordered by Doctor Johnson, and
310788 -                      the next treatment after MPA will be PARP
310789 -                      targeted to Millie's patient profile. ref SDS 92
310790 -                      VS9P
310792 -                       ..
310793 -                      [On 090716 2106 Millie notifies medical team that
310794 -                      UCSF delayed starting Millie's treatment with
310795 -                      PARP until September, because Millie suffered
310796 -                      painful breathing that might be caused by MPA so
310797 -                      this treatment ended before PARP protocol was
310798 -                      ready in September. ref SDS 93 EE6P
310800 -                       ..
310801 -                      [On 090909 Doctor Johnson advised that his
310802 -                      schedule had cleared to have enough time for
310803 -                      reviewing treatment options submitted on 090326,
310804 -                      and providing analysis comparing trade-offs in
310805 -                      order to prescribe treatment with the best chance
310806 -                      of being effective. ref SDS 94 VF60
310808 -                       ..
310809 -                      [On 090922 0810 Millie asks medical team about
310810 -                      progress starting PARP, and review of other
310811 -                      targeted therapies. ref SDS 95 NW6S
310813 -                       ..
310814 -                      [On 091027 0830 Doctor Johnson disclosed that
310815 -                      there still has not been enough time to review
310816 -                      follow on treatments for Millie, and that he has
310817 -                      not heard from Doctor Rugo on UCSF's progress
310818 -                      starting the PARP protocol. ref SDS 96 GN5G
310820 -                       ..
310821 -                      [On 100112 0830 Doctor Johnson reviews published
310822 -                      guidance on 2nd opinion PARP therapy targeted to
310823 -                      treat Millie's cancer with triple negavie patient
310824 -                      profile. ref SDS 97 N586
310826 -                 ..
310827 -            7.  Phase I study of CNF2024, an oral HSP 90 inhibitor;
310828 -                Memorial Sloan-Kettering Cancer Center, NY ; Dr.
310829 -                Shanu Modi, primary investigator; 212-639-5243
310831 -                 ..
310832 -            8.  Phase I study of Vaccinia virus injection into
310833 -                superficial tumors; University of Pittsburgh Cancer
310834 -                Institute; Herbert J. Zeh, MD, PhD, primary
310835 -                investigator; 412-692-2852 or zehh@upmc.edu
310837 -             ..
310838 -        c.  Vaccine clinical trials - new immunotherapy programs
310839 -
310840 -            1.  Phase I study of dendritic cell vaccine; Southern
310841 -                Cancer Center, Mobile, AL; Paul Schwarzenberger,
310842 -                MD, primary investigator; contact Judy Motlow
310843 -                251-433-9899
310845 -                 ..
310846 -            2.  Phase I study of mammaglobin-A DNA vaccine;
310847 -                Washington University; St. Louis, MO; primary
310848 -                investigator is William Gillanders, M.D. at 314-7470072
310849 -                or gillandersw@wustl.edu; very exciting
310850 -                possibility but not quite recruiting yet
310852 -                 ..
310853 -            3.  Phase I trial of Ad-sig-hMUC-1/ecdCD40L vaccine;
310854 -                Jonsson Cancer Center, UCLA; Sara Hurvitz, MD
310855 -                primary investigator; 888-798-0719; very exciting as
310856 -                Millie's cancer is very likely to MUC-positive since it is
310857 -                CA 15-3 positive
310859 -                 ..
310860 -            4.  Phase II study of vaccine with Aldesleukin; University
310861 -                of Minnesota; Tufia Haddad, MD, primary
310862 -                investigator; 612-624-2620
310864 -                 ..
310865 -            5.  Phase 1 study of CDX-1307 and hCG-B vaccine;
310866 -                Duke University, Durham, NC: Micheal Morse, MD,
310867 -                primary investigator; contact Nikki Adams, RN at
310868 -                313-916-8862; University of Pennsylvania,
310869 -                Philadelphia, PA; Angela DeMichelle, MD, primary
310870 -                investigator; contact Adri Recio, RN at 215-573-6760
310871 -                Novel therapy outside of clinical trials (using interventions
310872 -                with at least some clinical data support):
310874 -                 ..
310875 -            6.  Autologous vaccine (made from the patient's live
310876 -                tumor); Gustavo Moviglia, MD; main lab: Buenos
310877 -                Aires, Argentina; also has facilities in San Salvador;
310878 -                not covered by any U.S. insurance; expensive
310880 -             ..
310881 -        d.  Test Tissue for Most Effective Treatment, ref DRT 1 G26K
310882 -
310883 -            1.  Chemosensitivity testing of live tumor to determine
310884 -                which chemotherapy or targeted agent is most
310885 -                active against the tumor; Rational Therapeutics;
310886 -                Robert Nagourney, MD, medical director; contact
310887 -                Shari Burt at (562) 989-6455 x103
310889 -  ..
310890 - Previously, on 061201 considered tissue testing to evaluate most
310891 - effective cancer treatment. ref SDS 19 KT7J
310893 -  ..
310894 - 2nd Opinion continues...
310895 -
310896 -            2.  Molecular profile of tumor using paraffin-preserved
310897 -                tissue from previous biopsy or fresh live tumor; this
310898 -                test may help you find the cancer's Achilles heel;
310899 -                Caris/Molecular Profile Institute; (602) 358-8900; ask
310900 -                about their program where they don't charge you
310901 -                even if your insurance company won't cover it
310903 -             ..
310904 -        e.  Document/Liturature/Conference Review, ref DRT 1 444G
310905 -
310906 -            1.  San Antonio Breast Cancer Conference 12/2008;
310907 -                Abstract #2119 from MD Anderson; clomipramine, a
310908 -                commonly prescribed anti-depressant, targets the
310909 -                protein GSTpi which is found consistently and in high
310910 -                concentrations on triple-negative breast cancer cells
310912 -                 ..
310913 -            2.  San Antonio Breast Cancer Conference 12/2008;
310914 -                Abstract #3118 from MD Anderson; datasinib
310915 -                showed single-agent activity in women with
310916 -                advanced triple-negative breast cancer
310918 -         ..
310919 -    6.  ***Please note above research assumes the cancer is HER2
310920 -        negative.  The definitive test result (a FISH analysis done on
310921 -        the lymph node biopsy of 11/7/08) was not noted in the records.
310922 -        ref DRT 1 355K
310924 -  ..
310925 - Doctor Damen submitted documented confirmation of HER2 negative from
310926 - biopsy on 081107 with her letter on 081202. ref SDS 38 FG5G  These
310927 - results are listed in the record of Millie's patient history submitted
310928 - to Gwen on 090106. ref SDS 49 SW6O
310929 -
310930 -
310931 -
310932 -
310933 -
310934 -
310935 -
310936 -
310937 -
310938 -
310939 -
3110 -